FDA Puts Hold on KalVista’s Phase 2 Trial of KVD824 for HAE Attacks
The U.S. Food and Drug Administration (FDA) has placed a hold on KalVista Pharmaceuticals’ proposed Phase 2 trial of KVD824 — which the developer had expected to launch by the end of June. The trial is intended to test…